Zaltrap
E823215
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
All labels observed (1)
| Label | Occurrences |
|---|---|
| Zaltrap canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T9812300 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Zaltrap Context triple: [aflibercept, hasTradeName, Zaltrap]
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
C.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
D.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
E.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Zaltrap Target entity description: Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
C.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
D.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
E.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
- F. None of above. chosen
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
VEGF inhibitor
ⓘ
angiogenesis inhibitor ⓘ anti‑cancer drug ⓘ brand name drug ⓘ pharmaceutical drug ⓘ |
| administrationSchedule | every 2 weeks in combination with FOLFIRI ⓘ |
| approvalBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| approvedIn |
European Union
ⓘ
United States ⓘ
linked to:
United States of America
|
| brandNameOf | aflibercept ⓘ |
| coDevelopedBy | Sanofi ⓘ |
| commonAdverseEffect |
diarrhea
ⓘ
hypertension ⓘ neutropenia ⓘ proteinuria ⓘ stomatitis ⓘ |
| contraindication | severe hypersensitivity to aflibercept ⓘ |
| developedBy | Regeneron Pharmaceuticals ⓘ |
| firstApprovalYear | 2012 ⓘ |
| hasActiveIngredient | aflibercept ⓘ |
| hasATCCode | L01XX44 ⓘ |
| hasBlackBoxWarning |
compromised wound healing
ⓘ
gastrointestinal perforation ⓘ hemorrhage ⓘ |
| hasDosageForm | concentrate for solution for infusion ⓘ |
| indicatedForUseIn | adults ⓘ |
| indication | treatment of metastatic colorectal cancer resistant to or progressed after oxaliplatin-containing therapy ⓘ |
| legalStatus | prescription only ⓘ |
| marketedBy | Sanofi ⓘ |
| mechanismOfAction |
acts as a soluble decoy receptor for VEGF
ⓘ
inhibits angiogenesis by binding VEGF ⓘ |
| notIndicatedFor | pediatric patients ⓘ |
| originatorCompany | Regeneron Pharmaceuticals ⓘ |
| pharmacologicalClass |
anti‑VEGF agent
ⓘ
recombinant fusion protein ⓘ |
| pregnancyCategory | can cause fetal harm ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targets |
VEGF-A
ⓘ
linked to:
vascular endothelial growth factor A
VEGF-B ⓘ placental growth factor ⓘ vascular endothelial growth factor ⓘ |
| therapeuticArea | oncology ⓘ |
| treats |
colorectal cancer
ⓘ
metastatic colorectal cancer ⓘ |
| usedInCombinationWith |
FOLFIRI
ⓘ
linked to:
FOLFIRI regimen
chemotherapy ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Zaltrap Description of subject: Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.